Log In
BCIQ
Print this Print this
 

VT-1129

  Manage Alerts
Collapse Summary General Information
Company Viamet Pharmaceuticals Inc.
DescriptionOral small molecule inhibitor of fungal cytochrome P450 C-14 alpha demethylase (CYP51), which blocks production of ergosterol, a fungal cell wall component
Molecular Target Cytochrome P450 C-14 alpha demethylase (CYP51)
Mechanism of ActionCytochrome P450 C-14 alpha demethylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMeningitis
Indication DetailsTreat cryptococcal meningitis
Regulatory Designation U.S. - Fast Track (Treat cryptococcal meningitis);
U.S. - Orphan Drug (Treat cryptococcal meningitis);
U.S. - Qualified Infectious Disease Program (Treat cryptococcal meningitis)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/26/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today